The PFI Group Investment club

[jeriko]

NexMed, Inc. to Co-Sponsor Biotalk of Dr. Diego Miralles of Johnson & Johnson at the San Diego Biotechnology Discussion Group
Thursday, March 25, 2010

SAN DIEGO (Business Wire) -- NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, announced today that it will co-sponsor the Biotalk of G. Diego Miralles, M.D., Head of the Johnson & Johnson Pharmaceutical Research and Development (PRD) Discovery Unit, at the meeting of the San Diego Biotechnology Discussion Group (“SDBDG”) on Wednesday, March 31, 2010, from 5:30 p.m. to 8:00 p.m., at the Sorrento Summit in San Diego.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “We have long supported the mandate of the SDBDG, and are very pleased to be a co-sponsor of the upcoming Biotalk featuring Dr. Miralles. During the meeting, we will also debut the NexMed Biotech Partnering Initiative, which is intended to foster the development programs of emerging biotechnology companies utilizing the NexACT® delivery technology. We understand that early-stage companies may not have the necessary resources to advance their development programs. Under the NexMed Initiative, we will select partners who may opt to pay with equity and a revenue-sharing arrangement, for pre-clinical discovery work to be conducted by Bio-Quant which pairs their drug compounds with the NexACT® technology. We believe that this strategy has the potential to accelerate the use of NexACT as a leading drug delivery platform.”